New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.
A safer Alzheimer’s treatment may be on the horizon — but families still have meaningful choices today.
Many diagnosed patients won’t qualify — here are the
7 medical criteria.
New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.
New studies highlight smoother tolerability, easier routines, and practical safety updates that make the rivastigmine patch an increasingly caregiver-friendly option.
Three major GLP-1 trials came out in late 2025. One weight-loss drug slowed early Alzheimer’s decline, while two others failed. Surprisingly, this mixed pattern may point the way toward a promising new treatment direction.
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.
TEEPA SNOW: EXPLORE how touch has a profound impact on human connection in dementia care, with Teepa Snow, MS, OTR/L. Teepa shares why physical contact is vital and how there are different reactions to touch and need for touch. Discover the importance of understanding surprising reactions from people with dementia.
Lewis Hornby had a problem: his grandmother with dementia wasn’t drinking enough, causing her to get severely dehydrated.
Lewis Hornby had a problem: his grandmother with dementia wasn’t drinking enough, causing her to get severely dehydrated.
Dr. Richard Taylor has Alzheimer’s and the right attitude!
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to five years after an Alzheimer’s diagnosis. One medication significantly reduced the risk of developing severe dementia.
Researchers find optimistic people contribute to the health of their partners, staving off risk factors leading to Alzheimer’s disease, other dementias and cognitive decline as they grow old together.
No spam, only news and updates.
